Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$8.90MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel Anton de Boer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 166
- Beta
- 0.03
- Country
- NL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -3.49
Financials
Revenue
$8.90M+290.2%Net Income
$-8.87MEBITDA
$-8.25MFree Cash Flow
$-12.70MEPS (diluted)
$-0.08Shares Outstanding (diluted)
109.96M+371.0%Operating Expenses
$17.15MCash & Debt
$117.08MRevenue by Segment (annual)
$20.68MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $15.28M | $-40.52M | $-0.38 |
| 2024 | $18.91M | $-27.76M | $-0.34 |
| 2023 | $6.51M | $-28.12M | $-0.35 |
| 2022 | $3.59M | $-64.42M | $-0.91 |
| 2021 | $1.33M | $-60.74M | $-0.96 |
| 2020 | $1.03M | $-46.56M | $-0.93 |
| 2019 | $1.93M | $-56.75M | $-1.38 |
| 2018 | $4.94M | $-36.89M | $-1.08 |
| 2017 | $-1.53M | $-43.64M | $-1.72 |
| 2016 | $2.28M | $-39.10M | $-1.67 |
| 2015 | $9.41M | $-20.83M | $-0.89 |
| 2014 | $313.0K | $-12.13M | $-0.55 |
| 2013 | $0.00 | $-3.25M | $-0.15 |
Valuation
PRQRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (6)
- Newsmarketbeat.com·4d ago·Neutral
ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease ProQR Therapeutics NASDAQ: PRQR said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is developing NTCP programs for cholestatic liver diseases, initially focusing on pediatric biliary atresia.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
View source ↗ - Newsglobenewswire.com·13d ago·Negative
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor Appointments support ProQR's strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipeline AX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027 ProQR's expanded AI strategy is directly
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
ProQR to Participate in Upcoming Investor Conferences in September 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
View source ↗ - Newsseekingalpha.com·45d ago·Positive
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts I initiate ProQR Therapeutics N.V. with a Buy rating, driven by strong initial human proof-of-concept for its Axiomer RNA editing platform. The company's AX-0810 achieved 8-fold serum bile acid increases in phase 1, surpassing the 2-fold target and supporting its disease-modifying potential in biliary atresia [BA]. Upcoming catalysts include full phase 1 data for AX-0810 by end-2026, pediatric BA data from China in H1 20
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
ProQR Announces Second Quarter 2026 Operating and Financial Results LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the second quarter ended June 30, 2026, and provided a business update.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.11 per share
Typical surprise -12.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.10 vs $-0.13beat
- Tue, May 12$-0.15 vs $-0.15beat
- Thu, Mar 12$-0.09 vs $-0.08miss
- Thu, Nov 6$-0.12 vs $-0.10miss
- Thu, Aug 7$-0.14 vs $-0.08miss
- Thu, May 8$-0.11 vs $-0.09miss
Estimates and results for PRQR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PRQR officers and directors.
- Bought
- $1.3m
- Sold
- —
5 trades
0 trades
- De Boer Daniel Antonbought
- Filius Bartbought
- De Boer Daniel Antonbought
- De Boer Daniel Antonbought
- Filius Bartbought
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PRQR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.